MetaCap

Cue Biopharma (CUE) vs Grace Therapeutics (GRCE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grace Therapeutics (GRCE) has outperformed Cue Biopharma (CUE) over the past year, losing 46.4% versus a loss of 76.8%. Over five years, GRCE leads with a -79.3% price change compared with -98.9% for CUE. Grace Therapeutics is the larger company by market cap ($36.0 million vs $34.7 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CUE-76.75%GRCE-46.39%
+122%+14%-94%
Nov 21, 20251 yearNov 20, 2026
CUE-99.07%GRCE-80.48%
+5%-50%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CUE versus GRCE key metrics
MetricCUEGRCE
Share price$4.15$1.71
Market cap$34.69M$35.97M
1-day change-7.78%-0.58%
YTD return-54.64%-50.58%
1-year return-76.75%-46.39%
5-year return-98.92%-79.35%
EPS (TTM)$-27.80$-1.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$27.47M—
Revenue growth (YoY)+195.75%—
Net income (latest FY)$-26.60M$-7.79M
Operating margin-96.67%—
Net margin-96.85%—
52-week high$45.50$5.18
52-week low$2.83$1.64
Distance from 52-week high-90.88%-66.99%
Analyst consensusnonenone
Avg. price target upside+2020.48%+243.27%
Average volume567.02K119.27K
Shares outstanding8.36M21.04M
Employees295
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRCE has outperformed CUE by 30.4 percentage points over the past year.

About Cue Biopharma

CUE stock →

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees

About Grace Therapeutics

GRCE stock →

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

CUE vs GRCE FAQ

Which is bigger, Cue Biopharma or Grace Therapeutics?

Grace Therapeutics (GRCE) is larger, with a market capitalization of $35.97M compared with $34.69M for Cue Biopharma (CUE).

Which stock has performed better over the past year, CUE or GRCE?

GRCE returned -46.39% over the past 12 months, compared with -76.75% for CUE (price return, excluding dividends). Past performance does not predict future results.

Are Cue Biopharma and Grace Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons